Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 5 , Pages 496-501 , September 2009

Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group

  • Jeffrey M. Ignatoff, M.D., F.A.C.S.

      Affiliations

    • Northwestern University-Feinberg School of Medicine, Chicago, IL 60611, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-912-598-0651; fax: +1-912-598-0651
    • ,
  • Yu-Hui Chen, M.Ph., M.S.

      Affiliations

    • Dana Farber Cancer Institute, Boston, MA 02115, USA
    • ,
  • Richard Evan Greenberg, M.D.

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    • ,
  • Julio M. Pow-Sang, M.D.

      Affiliations

    • Moffitt Cancer Center, Tampa, FL 33612, USA
    • ,
  • Edward M. Messing, M.D.

      Affiliations

    • University of Rochester, Rochester, NY 14627, USA
    • ,
  • George Wilding, M.D.

      Affiliations

    • University of Wisconsin, Madison, WI 53706, USA

Received 8 February 2008 ,Revised 11 May 2008 ,Accepted 13 May 2008.

References 

  1. Dalbagni G. The management of superficial bladder cancer. Nat Clin Pract Urol. 2007;4:254–260
  2. Klein EA, Rogatko A, Herr HW. Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol. 1992;147:601–605
  3. Greenberg R, O'Dwyer P, Patterson L, et al. Intravesical AD 32 (N-trifluoroacetyladriamycin-14-valerate) in the treatment of patients with refractory bladder carcinoma—clinical efficacy, pharmacology, and safety. J Urol. 1995;153:233A;[Abstract]
  4. Greenberg RE, Bahnson RR, Wood D, et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology. 1997;49:471–475
  5. Patterson AL, Greenberg RE, Weems L, et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology. 2000;56:232–235
  6. Lamm DL, Riggs DR, Traynelis CL, et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol. 1995;153:1444–1450
  7. Perabo FG, Muller SC. Current and new strategies in immunotherapy for superficial bladder cancer. Urology. 2004;64:409–421
  8. Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol. 1985;134:40–47
  9. Durek C, Richter E, Basteck A, et al. The fate of bacillus Calmette-Guerin after intravesical instillation. J Urol. 2001;165:1765–1768
  10. Rischmann P, Desgrandchamps F, Malavaud B, et al. BCG intravesical instillations: Recommendations for side-effects management. Eur Urol. 2000;37(Suppl 1):33–36
  11. Carroll PR. Urothelial Cancers: Cancers of the renal pelvis, ureter, and bladder. In:  Tanagho EA,  McAnich J editor. Smith's General Urology. Norwalk, CT: Lange Medical Books; 1992;
  12. Nadler RB, Catalona WJ, Hudson MA, et al. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol. 1994;152:367–373
  13. Herr HW, Wartinger DD, Fair WR, et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer: A 10-year follow-up. J Urol. 1992;147:1020–1023
  14. Herr HW. Progression of Stage T1 bladder tumors after intravesical bacillus Calmette-Guerin. J Urol. 1991;145:40–43
  15. Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol. 2007;177:1283–1286
  16. Dalbagni G. The management of superficial bladder cancer. Nat Clin Pract Urol. 2007;4:254–260
  17. Shintani Y, Sawada Y, Inagaki T, et al. Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Guerin immunotherapy. Int J Urol. 2007;14:140–146
  18. Altay B, Girgin C, Kefi A, et al. The best management of superficial bladder tumors: Comparing TUR alone vs. TUR combined with intravesical chemotherapy modalities?. Int Urol Nephrol. 2000;32:53–58
  19. Amling CL. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer. 2001;25:219–278
  20. Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol Nefrol. 2004;56:65–72
  21. Lamm DL. Superficial bladder cancer. Curr Treat Options Oncol. 2002;3:403–411
  22. Israel M, Modest EJ, Frei E. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res. 1975;35:1365–1368
  23. Israel M, Khetarpal VK. Tissue distribution and metabolism of N-trifluoroacetyladriamycin-14-valerate (AD 32) compared with adriamycin in mice bearing established Lewis lung carcinomas tissue distribution and metabolism of N-trifluoroacetyladriamycin-14-valerate (AD 32) compared with adriamycin in mice bearing established Lewis lung carcinomas. Proceedings of the 13th International Congress of Chemotherapy, Vienna, Austria, Aug 28–Sept 2, 1983 [Abstract].
  24. Blum R, Garnick M, Israel M, et al. Preclinical Rationale and Phase I Clinical Trials of the Adriamycin Analog AD 32. In:  Carter S,  Sakurai Y,  Umezawa H editor. Recent Results in Cancer Research (New Drugs in Cancer Chemotherapy). New York: Springer Verlag; 1981;
  25. Greenberg RE, O'Dwyer PJ, Patterson AL. Intravesical AD 32 (N-trifluoroacetyladriamycin-14-valerate) in the treatment of patients with refractory bladder carcinoma—clinical efficacy, pharmacology, and safety. J Urol. 1995;153:233a
  26. Blum RH, Garnick MB, Israel M, et al. Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog. Cancer Treat Rep. 1979;63:919–923
  27. Garnick M, Griffin J, Sack M, et al. Phase II Evaluation of Ntrifluoroacetyladriamycin-14-valerate (AD 32). In:  Muggia F,  Young C,  Carter S editor. Anthracycline Antibiotics in Cancer Therapy. The Netherlands: Martinus Nijhoff; 1982;

☆ This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D.) and supported in part by Public Health Service grants CA23318, CA66636, CA21115, CA27525, CA11083, CA17145, CA21076 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PII: S1078-1439(08)00116-6

doi: 10.1016/j.urolonc.2008.05.004

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 5 , Pages 496-501 , September 2009

Article Tools